TL1A

TL1A

TL1A Overview

Molecule Name
Tumor necrosis factor superfamily member 15
Synonyms
TL1A, VEGI, TNFSF15
Drug Development Progress
Drugs in Clinical Trials18
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
VEGI192A,Vascular Endothelial Cell Growth Inhibitor,TNF Superfamily Ligand TL1A,TNFSF15,Tumor Necrosis Factor (Ligand) Superfamily, Member 15,Vascular Endothelial Growth Inhibitor-192A,VEGI,TL1A,Tumor Necrosis Factor Ligand 1B,TNLG1B,TNF Superfamily Member 15,Tumor Necrosis Factor Superfamily Member 15,TL1,TNF Ligand-Related Molecule 1,Tumor Necrosis Factor Ligand Superfamily Member 15,MGC129934,MGC129935
Background
TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.

TL1A Product List

Species
  • Human(7)
  • Cynomolgus / Rhesus macaque(2)
  • Mouse(2)
  • Rat(2)
  • Guinea pig(1)
  • Rabbit(1)
Tag
  • His Tag(11)
  • His Tag & Avi Tag(3)
  • Fc Tag(1)
Host
  • HEK293(15)
Conjugate
  • Unconjugated(12)
  • Biotin-labeled(3)
Grade
  • RUO(15)
Low Endotoxin
  • Yes(5)
  • No(10)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&PriceAdd to Cart
TL1A
Mouse TL1A / TNFSF15 Protein, His Tag, low endotoxin (HPLC verified)
Mouse
HEK293
HPLCSDS-PAGE
ELISASPR

$415.00

100ug
TL1A
HOTAvitag
TLA-H52Q1
Biotinylated Human TL1A / TNFSF15 Protein, His,Avitag™
Human
HEK293
SDS-PAGE
ELISASPR

$415.00

25ug
TL1A
Cynomolgus/Rhesus macaque TL1A / TNFSF15 Protein, His Tag, low endotoxin (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISASPR

$415.00

100ug
TL1A
Human TL1A / TNFSF15 Protein, His Tag, active trimer, ultra low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRCELL BASE

$415.00

100ug
TL1A
Avitag
TLA-C82E3
Biotinylated Cynomolgus/Rhesus macaque TL1A / TNFSF15 Protein, Avitag™,His Tag (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$140.00

25ug
TL1A
Guinea pig TL1A / TNFSF15 Protein, His Tag (MALS verified)
Guinea pig
HEK293
MALSSDS-PAGE

$415.00

100ug
TL1A
Human TL1A / TNFSF15 Protein, His Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$415.00

100ug
TL1A
Human TL1A / TNFSF15 Protein, His Tag
Human
HEK293
SDS-PAGE

$380.00

100ug
TL1A
Human TL1A / TNFSF15 Protein, His Tag (Monomer) (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$415.00

100ug
TL1A
Human TL1A / TNFSF15 Protein, His Tag (Monomer) (HPLC verified)
Human
HEK293
HPLCSDS-PAGE
ELISA

$415.00

100ug
You Have Viewed 1-10 Of 15 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

What is soluble TREM2 (sTREM2), and how is it related to TREM2 signaling?

Soluble TREM2 (sTREM2) is generated through the cleavage and shedding of the membrane-bound TREM2 receptor. TREM2 shedding can regulate the amount of receptor available on the cell surface and influence TREM2 signaling. sTREM2 can also be detected in biological fluids and has been investigated as a potential biomarker of microglial activation and TREM2-related changes in neurodegenerative diseases.

How is TREM2 associated with Alzheimer’s disease?

TREM2 is an important genetic and biological risk factor in Alzheimer’s disease (AD). Rare variants in TREM2, including loss-of-function variants, are associated with increased risk of late-onset AD. TREM2 signaling influences microglial survival, activation, lipid metabolism, and responses to amyloid pathology, making TREM2 an important target for studying microglial dysfunction and therapeutic strategies in AD.

What is TREM2, and what is its role in microglia and macrophages?

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a cell-surface receptor expressed primarily on microglia and other tissue-resident macrophages. TREM2 signaling regulates myeloid cell survival, proliferation, metabolism, phagocytosis, and responses to tissue damage. In the central nervous system, TREM2 is an important regulator of microglial function and homeostasis, while its expression in peripheral macrophages supports immune and tissue responses.

How does the P301L mutation affect Tau aggregation and disease modeling?

P301L is a pathogenic Tau mutation associated with familial frontotemporal dementia and other tauopathies. The mutation can increase the aggregation propensity of Tau and is widely used to study Tau misfolding and pathological aggregation. Recombinant P301L Tau proteins and P301L-containing PFFs can support cell-based, organoid and animal models for investigating Tau aggregation, seeding mechanisms, and potential therapeutic interventions.

How can I study different forms of Tau in neurodegenerative disease research?

Different forms of Tau can be investigated to model distinct aspects of Tau pathology. Recombinant Tau proteins with specific isoforms, disease-associated mutations, or phosphorylation states can be used to study Tau structure, aggregation, and molecular interactions. Phosphorylated Tau antibodies help detect and characterize disease-associated Tau species, while Tau stable cell lines provide cell-based models for studying intracellular Tau aggregation and evaluating potential therapeutic effects.
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
DuvakitugTEV-48574; TEV-'574; TEV'574; SAR447189; SAR-447189; TEV574; TEV-574Phase 3 ClinicalTeva Pharmaceutical Industries Ltd
Asthma; Colitis, Ulcerative; Crohn Disease
Details
TulisokibartPRA-023; MK-7240; PRA023Phase 3 ClinicalMerck Sharp & Dohme LLC, Prometheus Biosciences Inc
Arthritis, Psoriatic; Arthritis, Rheumatoid; Axial Spondyloarthritis; Colitis, Ulcerative; Crohn Disease; Hidradenitis Suppurativa; Inflammatory Bowel Diseases; Lung Diseases, Interstitial; Non-radiographic axial spondyloarthritis; Scleroderma, Diffuse; Spondylitis, Ankylosing
Details
AfimkibartPF-06480605; PF 6480605; RVT-3101; RG-6631; RO-7790121Phase 3 ClinicalPfizer Inc
Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Inflammatory Bowel Diseases; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
RO-7837195RO-7837195; RO7837195Phase 2 ClinicalGenentech Inc
Colitis, Ulcerative
Details
PF-07261271RG-6730; PF-07261271Phase 2 ClinicalPfizer Inc
Inflammatory Bowel Diseases
Details
SPY0-72SPY002-072; SPY0-72Phase 2 ClinicalSpyre Therapeutics Inc
Arthritis, Psoriatic; Arthritis, Rheumatoid; Axial Spondyloarthritis; Joint Diseases; Rheumatic Diseases
Details
XmAb-942XmAb942; XmAb-942Phase 2 ClinicalXencor Inc
Colitis, Ulcerative; Inflammatory Bowel Diseases
Details
BCD-261BCD-261Phase 2 ClinicalBIOCAD JSC
Colitis, Ulcerative; Crohn Disease; Inflammatory Bowel Diseases
Details
next-generation anti-TL1A mAb (Pfizer)Phase 1 ClinicalPfizer Inc
Fibrosis; Inflammation
Details
ENV-6946ENV-6946Phase 1 ClinicalEnveda Biosciences Inc
Inflammatory Bowel Diseases
Details
QX-030NQX030N; CLD-423; QX-030NPhase 1 ClinicalQyuns Therapeutics Co Ltd
Autoimmune Diseases; Inflammatory Bowel Diseases
Details
HXN-1001HXN-1001Phase 1 ClinicalHelixon Ltd
Inflammatory Bowel Diseases; Psoriasis
Details
GR-2303GR-2303Phase 1 ClinicalChongqing Genrix Biopharmaceutical Co Ltd
Inflammatory Bowel Diseases
Details
SSGJ-627SSGJ-627; SSGJ627Phase 1 ClinicalSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Colitis, Ulcerative
Details
SPY-002SPY002-091; SPY002 072; SPY-002; PR-010Phase 1 ClinicalParagon Therapeutics Inc
Details
ABS-101(Absci)ABS-101(Absci); ABS-101Phase 1 ClinicalAbsci Corp
Inflammatory Bowel Diseases
Details
FG-M701FG-M-701; ABBV-701; FG-M701Phase 1 ClinicalFutureGen Biopharm (Beijing) Co Ltd
Autoimmune Diseases
Details
Next-generation anti-TL1A antibody(Telavant)Phase 1 ClinicalTelavant Inc
Fibrosis; Inflammation
Details
Customer Reviews